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groups according to the relative PV change in device seg-
ment: PV “increased” >+5% (PVI), PV unchanged ±5% 
(PVU), and PV decreased <−5% (PVD). The change 
in PV was re-evaluated three times: after subtraction of 
theoretical device volume, after analysis of echogenicity 
based on brightness function. In 449 patients, 483 lesions 
were analyzed pre- and post-implantation. “PVI” was 
more frequently observed in BVS (53.8%) than EES group 
(39.4%), p = 0.006. After subtraction of the theoretical 
device volume, the frequency of “PVI” decreased in both 
BVS (36.2%) and EES (32.1%) groups and became com-
parable (p = 0.581). In addition, the percentage of “PVI” 
was further reduced in both device groups after correction 
for either radiofrequency backscattering (BVS 34.4% vs. 
EES 22.6%) or echogenicity (BVS 25.2% vs. EES 9.7%). 
Abstract The purpose of the study to assess the compara-
bility of immediate changes in plaque/media volume (PV) 
on three modalities of intravascular ultrasound (IVUS) 
after implantation of either bioresorbable vascular scaf-
fold (BVS) or everolimus-eluting metallic stent (EES) in 
Absorb II Study. The two devices have different device vol-
ume and ultrasound backscattering that may interfere with 
the “plaque/media” assessed by three modalities on IVUS: 
grayscale, backscattering of radiofrequency and brightness 
function. In a multicenter randomized controlled trial, 501 
patients with stable or unstable angina underwent docu-
mentary IVUS pre- and post- implantation. The change 
in plaque/media volume (PV) was categorized into three 
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PV change in device segment was differently affected by 
BVS and EES devices implantation due to their differences 
in device volume and ultrasound backscattering. It implies 
that the lumen volume was also artifactually affected by the 
type of device implanted. Comparative IVUS assessment 
of lumen and plaque/media volume changes following 
implantation of BVS and EES requires specific methodo-
logical adjustment.
Keywords IVUS · Plaque/media volume · Absorb II · 
Bioresorbable vascular scaffold
Abbreviations
BVS  Bioresorbable vascular scaffold
EES  Everolimus-eluting metallic stent
QCA  Quantitative coronary angiography
VH-IVUS  Virtual histology-intravascular ultrasound
ROI  Region of interest
PV  Plaque/media volume
PVI  Plaque volume increased
PVU  Plaque volume unchanged
PVD  Plaque volume decreased
Introduction
IVUS has been applied universally to understand coronary 
atherosclerosis, to recognize high-risk plaque features and 
to evaluate stent placement [1, 2]. IVUS measurements are 
performed at the leading edge of the ultrasonic interface, as 
the differential echogenic signal across the leading edge is 
more obvious and reproducible [3, 4]. After implantation of 
a metallic stent, the lumen contour is conventionally deline-
ated along the endoluminal leading edge of the device, as 
it is difficult to distinguish the trailing edge due to the high 
ultrasonic backscattering of the metal. Therefore, the inter-
ference of the metal on the ultrasound renders the assess-
ment of luminal and plaque/media measurements less accu-
rate [3, 5].
By nature, polymeric material made of polylactide has 
a different ultrasonic interference on luminal and plaque/
media measurements. In addition, differences in strut thick-
ness, footprint area, device size, volume, and mass between 
metallic stent and polymeric scaffold may also have spe-
cific impact on luminal and plaque/media measurements [3, 
6].
Whether different device volume and ultrasound back-
scattering in the two devices have differential impact on 
the grayscale-IVUS assessment of lumen and plaque/media 
remains to be investigated.
In the ABSORB II randomized trial (Clinical Trials. gov 
NCT01425281), pre- and post-procedural documentary 
IVUS imaging were mandatory. The aim of this study is 
to evaluate the difference in plaque/media volume change 
immediately after implantation of either bioresorbable vas-




The ABSORB II trial is a prospective, single-blind, mul-
ticenter clinical trial that randomized patients to PCI with 
either BVS or EES in a 2:1 fashion. The trial design has 
been described in detail previously [6, 7]. In brief, the pro-
tocol of the trial allowed the treatment of up to two de-novo 
native coronary artery lesions, all with an angiographic 
maximal luminal diameter between 2.25 and 3.8  mm as 
estimated by online quantitative coronary angiography 
(QCA) and a lesion length of ≤48 mm. All patients under-
went documentary grayscale-IVUS assessment before and 
after device implantation [6, 7].
Study devices
The second-generation Absorb BVS is arranged as in-
phase zigzag hoops linked together by three longitudinal 
bridges. Detail information of the device has been pub-
lished [7]. The control device, EES, share its same basic 
MULTI-LINK design, and both devices are similar in 
terms of drug type, drug dose density, and elution profile. 
The metallic platform is made of cobalt chromium alloy. 
However, there are differences between the two devices in 
terms of device volume, mass, footprint, thickness proper-
ties, e.g.: (1) physically the strut thickness of the scaffold is 
approximately 150 µm, whereas the strut thickness of EES 
is 81 µm [7]; (2) the device volume of the BVS is approxi-
mately three times larger than the EES device for same 
nominal device size (Table 3).
IVUS image acquisition, analysis and definitions
IVUS was mandatory pre- and post-implantation. In brief, 
IVUS data was acquired with a 3.2-French, 45-MHz rota-
tional IVUS catheter (Revolution® 45 MHz; Volcano Cor-
poration, Rancho Cordova, CA). IVUS data was acquired 
with a pullback speed of 0.5  mm/s and a frame speed of 
30 frames/s.
Quantitative IVUS analysis was performed using a 
dedicated software (QCU-CMS-Research software v4.69, 
Medis, Leiden, The Netherlands) as described previously 
[3, 5]. The region of interest (ROI) was defined as in-device 
segment. The pre-procedure device segment was co-local-
ized and matched with post-implantation using identical 
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landmarks such as side branches, calcification, pericar-
dium, vein, and plaque shape [3, 5]. All pullbacks were 
analyzed off-line by an independent core laboratory (Cardi-
alysis BV, Rotterdam, The Netherlands).
The absolute change in IVUS measurements between 
pre- and post-implantation was calculated as post-implan-
tation values minus pre-procedure values. Plaque volume 
(PV) was normalized by segment length when comparison 
was performed between BVS and EES groups. Normal-
ized plaque/media volume = [(total vessel volume − total 
lumen volume)]/segment length × mean segment length in 
the whole population [8–11]. Relative change was calcu-
lated as absolute change divided by pre-procedure values. 
In previous studies, the standard deviation of intra and 
inter-observer variability of the IVUS measurements of 
plaque/media has been reported to be between 2.9 and 5%. 
To account for this variability with a conservative margin, 
relative increase or decrease in plaque/media volume was 
considered when a change larger than ±5.0% was observed 
[12–14]. The PV change was, thus, categorized into three 
groups: PV “increased” (PVI), PV unchanged (PVU) and 
PV decreased (PVD).
VH-IVUS analysis
On VH-IVUS analysis, four major tissue components 
(fibrous: green; fibrofatty: light green; dense calcium, 
DC: white; and necrotic core: red) were characterized and 
compared between the two groups [15]. Post implantation 
pseudo “DC” was defined as confluent, non-interrupted 
white color surrounded by red color, located near the lumen 
contour not present at preprocedure images (Fig.  3, panel 
c). Dense calcium located behind the struts and separated 
from the struts was considered as real DC [16].
Automatic quantitative echogenicity (EG) analysis 
on IVUS
The principle of EG has been previously described [17, 
18]. EG aims to classify the vessel wall components located 
between the luminal boundary and the EEM into categories 
based on their grey-scale intensity level in B-mode IVUS 
images. Five tissue types were quantified: calcified, hypere-
chogenic, upperechogenic, hypoechogenic, and unknown [19].
Re-evaluation of the plaque/media volume
Three types of PV re-evaluations were performed to cor-
rect for the artificial overestimation of the plaque/media 
volume on IVUS related to the strut volume counted as 
plaque/media and backscattering: first, we subtracted 
from the PV post-implantation the theoretical device 
volume disclosed by the manufacturer; second, we sub-
tracted the post-procedural “increase in volume of VH 
pseudo “DC” (∆DC = post − pre)”, generated by the radi-
ofrequency backscattering of polymeric or metallic struts, 
that has been considered as a surrogate assessment of the 
struts presence [20]; third, we subtracted the increase in 
volume of Upper + Hyper echogenicity (∆ Upper + Hyper 
EG = post − pre), which can be used as another surrogate 
for the device presence [19]. (Fig. 3).
Statistical analysis
All analyses were performed on the intention-to-
treat basis, using all patients randomized in the study, 
regardless of the treatment actually received. The Kol-
mogorov–Smirnov test was used to evaluate the nor-
mality assumption of all continuous variables. All con-
tinuous variables were presented as mean ± standard 
deviation. One-way ANOVA with Tukey’s post-hoc 
test or Kruskal–Wallis test were used for comparisons 
of continuous variables. The counts of relative change 
in PV were summarized and tabulated according to the 
frequency; Chi square test was used for categorical vari-
ables. All statistical tests were performed with SPSS ver-
sion 22 (IBM Corp, Armonk, NY). A 2-sided p value of 
<0.05 was considered to indicate statistical significance.
Results
Patient and lesion characteristics
In the ABSORB II trial, a total of 501 patients were 
included (BVS 335 patients, 67%; EES 166 patients, 33%). 
Grayscale-IVUS imaging pre- and post-implantation was 
available in 449 patients with 483 lesions with 318 (66%) 
lesions being treated with BVS and 165 (44%) lesions 
treated with EES (Fig.  1). This comprises the population 
of the present study. Overall, mean age was 63 ± 10 years, 
76.6% were male and 22.9% were diabetics. Unstable 
angina according to the Braunwald classification was the 
clinical presentation in 20.7% of cases. The study arms 
were well balanced with regard to baseline clinical charac-
teristics (Table 1).
IVUS measurements pre- and post-implantation
On pre-implantation IVUS, average plaque/media vol-
ume was smaller in the BVS group (154.7 ± 58.7  mm3 
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Fig. 1  Study flow chart. BVS bioresorbable vascular scaffold, EES everolimus-eluting stent, IVUS intravascular ultrasound
Table 1  Baseline patient characteristics in Absorb II study (449 patients, 483 lesions)
Data are shown in n (%) or mean ± SD
BVS bioresorbable vascular scaffold, EES everolimus-eluting metallic stent, CHD coronary heart disease
449 patients BVS (297 patients) EES (152 patients) p value
Age, years 63.6 ± 10.1 63.6 ± 9.9 0.987
Male, n (%) 223 (75.1%) 121 (79.6%) 0.346
Hypertension, n (%) 191 (64.3%) 102 (67.1%) 0.804
Hypercholesterolemia, n (%) 208 (70%) 112 (73.7%) 0.328
Diabetes mellitus, n (%) 65 (21.9%) 38 (25%) 0.458
Myocardial infarction history, n (%) 80 (26.9%) 46 (30.3%) 0.596
Cardiac Intervention history, n (%) 102 (34.3%) 54 (35.5%) 0.834
Current smokers, n (%) 76 (25.6%) 34 (22.4%) 0.118
Family history of CHD, n (%) 99 (33.3%) 56 (36.8%) 0.76
Clinic presentation, n (%) 0.629
 Stable angina 192 (64.6%) 98 (64.5%)
 Unstable angina 60 (20.2%) 33 (21.7%)
 Silent ischemia 35 (11.8%) 19 (12.5%)
483 lesions BVS (318 lesions) EES (165 lesions) p value
Target vessel 0.166
 Left anterior descending, n (%) 89 (28%) 80 (48.5%)
 Left circumflex, n (%) 148 (46.5%) 34 (20.6%)
 Right coronary artery, n (%) 81 (25.5%) 51 (30.9%)
AHA/ACC lesion classification 0.197
 A, n (%) 4 (1.3%) 1 (0.6%)
 B1, n (%) 184 (57.9%) 83 (50.3%)
 Type B2/C lesion, n (%) 130 (40.9%) 81 (49.1%)
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vs. 168.8 ± 62.6  mm3; p = 0.015). Average PV showed a 
higher increase in the BVS group (ΔPV 8.8 ± 16.1  mm3 
vs. 2.2 ± 18.1  mm3; p < 0.001) and at post-implantation, 
there was no difference in average PV in both arms (BVS 
163.5 ± 56.9  mm3 vs. EES 170.9 ± 56.4  mm3; p = 0.172). 
Increase in PV was observed in BVS in 53.8% of cases and 
in EES in 39.4% of cases, p = 0.006 (Fig. 2).
PV changes after correction for device volume
Subtraction of theoretical device volume
Average theoretical device volume was 9.4 ± 1.0  mm3 
in the BVS group and 2.8 ± 1.0  mm3 in the EES group 
(p < 0.001). After subtraction of theoretical device volume, 
delta PV was no longer different between the two study arm 
(BVS ∆PV 0.6 ± 14.6 mm3 vs. EES ∆ PV 0.5 ± 15.9 mm3; 
p = 0.963) (Table  2). However, the frequency of this 
“increase” in average PV was reduced to 36.2% in the BVS 
arm and 32.1% in the EES arm; p = 0.581.
Subtraction of pseudo dense calcium on Virtual 
Histology‑IVUS
Average pseudo “dense calcium” volume was compa-
rable in the two groups (BVS 8.3 ± 6.0  mm3 vs. EES 
8.0 ± 5.6  mm3; p = 0.605). After subtraction of pseudo 
“dense calcium” volume, delta PV was different between 
the two study arms (BVS ∆PV 0.65 ± 16.8  mm3 vs. EES 
∆PV −5.7 ± 18.7 mm3; p < 0.001). However, the frequency 
of “increase” in average PV was reduced to 34.4% in the 
BVS and 22.6% in the EES arms; p = 0.004.
Subtraction of pseudo “Upper + Hyper echogenicity”
Average pseudo “Upper + Hyper echogenicity” volume in 
BVS group (12.5 ± 12.6 mm3) was significantly less than in 
EES group (18.4 ± 10.5 mm3), p < 0.001.
Fig. 2  Cumulative frequency distribution curves of absolute ΔPV 
(mm3) pre- and post-implantation in device segment in BVS and 
EES groups. In BVS group, more than 70% of the lesions showed PV 
“increase” post-implantation; in EES group, approximately 50% of 
the lesions showed PV “increase” post-implantation. BVS bioresorba-
ble vascular scaffold, EES everolimus-eluting stent, PV plaque/media 
volume
Table 2  IVUS measurements 
pre- and post-implantation in 
Absorb II study (449 patients, 
483 lesions)
Data are shown in n (%) or mean ± SD
BVS bioresorbable vascular scaffold, EES everolimus-eluting metallic stent, PVI plaque volume increase
BVS 318 lesions EES 165 lesions p value
Plaque volume
 Pre-procedure (mm3) 154.7 ± 58.7 168.8 ± 62.6 0.015
 Post-procedure (mm3) 163.5 ± 56.9 170.9 ± 56.4 0.172
 Δ post-pre procedure (mm3) 8.8 ± 16.1 2.2 ± 18.1 <0.001
 Relative Δ post-pre procedure (%) 7.7 ± 12.9 3.6 ± 14.0 0.001
“PVI”, n (%) 171, 53.8% 65, 39.4% 0.006
Vessel volume
 Pre-procedure (mm3) 262.8 ± 78 281.1 ± 77.9 0.015
 Post-procedure (mm3) 302 ± 82.1 328.1 ± 82.1 0.001
 Δ post-pre procedure (mm3) 39.2 ± 20.7 47 ± 20.6 <0.001
 Relative Δ post-pre procedure (%) 16.1 ± 9.7 17.8 ± 8.8 0.056
Mean lumen volume
 Pre-procedure (mm3) 108.1 ± 31.1 112.3 ± 32 0.162
 Post-procedure (mm3) 138.5 ± 33.3 157.2 ± 36.4 <0.001
 Δ post-pre procedure (mm3) 30.4 ± 19.7 44.8 ± 22.8 <0.001
 Relative Δ post-pre procedure (%) 31.5 ± 22.8 44.2 ± 27.3 <0.001
Plaque burden (%) 57.1 ± 8.6 58.6 ± 8.8 0.077
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Table 3  IVUS measurements of plaque volume in device segment pre- and post-implantation after re-evaluations in Absorb II study (449 
patients, 483 lesions)
Data are shown in n or mean ± SD. The volume value was normalized by the mean of segment length in the all population
BVS bioresorbable vascular scaffold, EES everolimus-eluting metallic stent, PV plaque volume, DC dense calcium, VH-IVUS virtual histology-
IVUS, Pseudo “PVI” pseudo “plaque volume increase”
*VH-IVUS analysis are available in 453 lesions, BVS = 294 lesions, EES = 159 lesions
BVS 318 lesions EES 165 lesions p value
Subtraction of theoretic device volume
 Theoretic device volume (mm3) 9.4 ± 1.0 2.8 ± 1.0 <0.001
 Post PV subtraction of the theoretic device volume (mm3) 154.0 ± 56.6 168.2 ± 56.2 0.009
 ∆PV post-pre after subtraction of the theoretic device volume (mm3) 0.60 ± 14.6 0.53 ± 15.9 0.963
 Relative ∆PV post-pre after subtraction of the theoretic device volume (%) 1.5 ± 15.2% 1.3 ± 16.2% 0.904
 p Value pre vs. post subtraction of the theoretic device volume 0.445 0.665
 Pseudo “PVI”, lesions, n(%) 115, 36.2% 53,32.1% 0.581
Subtraction of pseudo “DC” on VH-IVUS*
 Pseudo “DC” on VH (mm3) 8.3 ± 6.0 8.0 ± 5.6 0.605
 Post PV subtraction of the pseudo “DC” (mm3) 155.7 ± 57.7 162.9 ± 57.7 0.209
 ∆PV post-pre after subtraction of the pseudo “DC” (mm3) 0.65 ± 16.8 −5.7 ± 18.7 <0.001
 Relative ∆PV post-pre after subtraction of the pseudo “DC” (%) 1.7 ± 13.3 −2.0 ± 14.2 0.007
 p Value pre vs. post after subtraction pseudo “DC” 0.509 <0.001
 Pseudo “PVI”, n (%) 101, 34.4% 36, 22.6% 0.004
Subtraction of pseudo “Upper + Hyper EG” on echogenicity
 Pseudo “Upper + Hyper” volume (mm3) 12.5 ± 12.6 18.4 ± 10.5 <0.001
 Post PV subtraction of pseudo “Upper + Hyper” volume (mm3) 151.0 ± 53.5 152.5 ± 53.6 0.769
 ∆PV post-pre after subtraction of pseudo “Upper + Hyper” (mm3) −3.7 ± 18.8 −16.3 ± 21.4 <0.001
 Relative ∆PV post-pre after subtraction of pseudo “Upper + Hyper” (%) −0.77 ± 13.7 −8.3 ± 12.5 <0.001
 p Value pre vs. post after subtraction of pseudo “Upper + Hyper” <0.001 <0.001
 Pseudo “PVI”, n (%) 80, 25.2% 16, 9.7% <0.001
Fig. 3  Examples showing the overestimation and re-evaluations 
of plaque/media volume after implantation. The PA was over esti-
mated from 7.4 to 8.7 mm2, as well as the PB (Pre: 58.2% vs. 64.9%) 
(Panels a, b). As IVUS lacks the necessary resolution to detect the 
true lumen border by differentiating the abluminal boundaries of 
device struts. The lumen contour is conventionally delineated along 
the endoluminal leading edge of the device. Therefore, device vol-
umes and their backscattering are artifactually defined as “plaque/
media volume” and was overestimated on grayscale-IVUS. PA was 
re-evaluated after subtraction of the pseudo “DC” on VH-IVUS and 
the Upper + Hyper EG which are surrogates for the device presence 
in both lesions (Panels c, d). One of the disadvantage of VH-IVUS 
is the default presence of medial stripe that masks and hides some of 
the struts in direct contact with the adventitia. Echogenicity is able to 
assess the plaque/media area without the hiding effect of the medial 
stripe of VH-IVUS. VA vessel area, LA lumen area, PA plaque/media 
area, PB plaque burden, VH-IVUS virtual histology-IVUS, EG echo-
genicity. *Side branches; DC dense calcium
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After subtraction of pseudo “Upper + Hyper echo-
genicity” volume, delta PV was different between the two 
study arms (BVS ∆PV −3.7 ± 18.8  mm3 vs. EES ∆PV 
−16.3 ± 21.4 mm3; p < 0.001). The frequency of “increase” 
in average PV was drastically less than before subtraction 
in both device arms (BVS 25.2% vs. EES 9.7%; p < 0001) 
(Table 3).
Discussion
In the present study, we evaluated how the plaque/media 
volume changes following implantation of either BVS or 
EES. The major findings of this study are the following: 
(1) acute plaque/media volume change after implantation 
was differently influenced by the device: plaque/media vol-
ume overestimation was more frequently observed in BVS 
than in EES groups, due to different device volumes and 
ultrasound backscattering. (2) re-evaluations could be per-
formed to minimize the overestimation of plaque/media 
volume.
Plaque/media volume overestimation after implantation
Before correction for the device volume and backscattering, 
plaque/media volume “increase” was observed in both BVS 
and EES arms. The possible explanation is that IVUS lacks 
the necessary resolution to detect the true lumen border by 
differentiating the abluminal boundaries of device struts. 
Therefore, device volumes and their backscattering are arti-
factually defined as “plaque/media volume” on grayscale-
IVUS (Fig. 4a, a′) [5].
This artificial plaque/media volume overestimation was 
more frequently observed in BVS group than in EES group, 
due to the fact that the device volume of the BVS is more 
than three times larger than the EES device for same nomi-
nal device size.
Re-evaluations were applied to minimize the plaque/
media overestimation
After correction for the theoretical device volume, there 
was no longer significant difference in ∆PV between BVS 
and EES groups. They presented comparable percentage 
of plaque/media overestimation. However, even after cor-
rection for the theoretical device volume, PV “increase” 
was still observed in more than 1/3 of the lesions in both 
device arms, due to device backscattering on IVUS.
Re-evaluations were further performed to subtract of 
the device appearance on backscattering virtual histol-
ogy-IVUS, based on the fact that device struts are artifac-
tually presented as pseudo “DC” on VH [16, 20]. After 
re-evaluation, the overestimation of PV was minimized 
in both device groups. Nevertheless, one of the disad-
vantages of VH is the default presence of a medial grey 
stripe that masks and hides some of the struts in direct 
Fig. 4  Compared to OCT, IVUS overestimates the plaque/media. 
Panels a and a′ show one patient who had undergone both IVUS 
(20  MHz) and OCT investigation, one cross section was matched 
using the side branch [5]. The lumen contour on IVUS mainly relies 
on the highly reflective endoluminal surface of the polymeric strut 
and may lack the necessary imaging resolution to detect the true 
boundaries of the vessel wall between the protruding polymeric 
struts. Therefore, IVUS may underestimate the lumen area and con-
versely overestimates the plaque/media area. In contrast, the contour 
of the true flow lumen area on OCT does not include artifactually the 
space filled with blood flowing between the protruding polymeric 
struts [5, 21]. SB side branch Reprinted with permission from Serruys 
et al. [5]
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contact with the adventitia affecting the results of this 
correction (Fig. 3).
Similarly to VH, device struts appear as pseudo 
“Upper + Hyper echogenicity” on echogenicity analy-
ses, which has been previously validated [5, 19, 21, 22]. 
On further re-evaluation after correction for the pseudo 
“Upper + Hyper echogenicity”, the frequency of plaque/
media volume “increase” was significantly reduced. The 
advantage of echogenicity is that it is able to assess the 
plaque/media area without the hiding effect of the medial 
stripe of the VH-IVUS (Fig. 3).
Nonetheless, even after re-evaluations, PV overestima-
tions persisted in both groups. This was due to the space 
between struts being still artifactually defined as “plaque/
media” given the limited resolution of IVUS as mentioned 
above. In contrast, the contour of the true lumen area on 
OCT does not include artifactually the space filled with 
blood flowing between the protruding struts (Fig. 4) [5, 21]. 
Hybrid catheter co-registration of the two imaging modali-
ties could, thus, provide a more accurate assessment of the 
lumen and plaque/media measurements [23]. Before hybrid 
are available in clinical, OCT may be an alternative, despite 
possibly limited imaging of larger plaque or thickened wall.
Interestingly, the correction using the theoretical device 
volume yielded different results when compared to the 
correction using VH or EG. This happened because while 
the theoretical device volumes of EES and BVS are sig-
nificantly different (BVS is more than three times larger), 
this difference is reduced in the in vivo images mainly due 
to the relatively low resolution of IVUS. For that reason, 
PMV changes behave differently following correction using 
these different methods.
Study strengths and limitations
Our study must be viewed in light of some limitations. The 
ABSORB II trial included mostly patients with less com-
plex coronary lesions and our findings might not be extrap-
olated to more complex scenarios. Furthermore, we do not 
provide a comparison with a gold-standard method of acute 
plaque/media changes after BVS and EES implantation. 
However, such a method is still unavailable in clinical prac-
tice. Moreover, our study derives from a solid database of a 
large randomized controlled trial and our data was analyzed 
by an independent core laboratory.
Conclusion
Acute plaque/media volume change was differently 
affected by BVS and EES devices implantation due to their 
differences in device volume and ultrasound backscattering 
patterns. This implies that the lumen volume may also be 
artificially affected by the implanted device. Comparative 
assessment of lumen and plaque/media change on IVUS 
following BVS and EES implantation requires methodo-
logical adjustment. Hybrid catheters that combine OCT 
and IVUS images could potentially provide a more accu-
rate assessment of the respective mechanical performances 
of each device.
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